Precision BioSciences: Potential Proof-Of-Concept Data For HBV Cure In 2026 [Seeking Alpha]
Precision BioSciences, Inc. (DTIL)
Last precision biosciences, inc. earnings: 11/12 07:15 am
Check Earnings Report
Company Research
Source: Seeking Alpha
PBGENE-HBV targets both cccDNA and integrated HBV DNA, aiming for a functional HBV cure superior to downstream competitors. Recent $75M capital raise extends DTIL's cash runway through major readouts, supporting continued clinical development and operational flexibility. Risks include potential safety events, competitive efficacy, and uncertain milestone/royalty revenue from partnered programs. quantic69/iStock via Getty Images Thesis Overview Precision BioSciences ( DTIL ) is developing gene therapies based on its ARCUS genome editing platform. Lead candidates are PBGENE-HBV, a potential hepatitis B virus (HBV) cure, as well as PBGENE-DMD, a differentiated in vivo gene editing therapy for Duchenne Muscular Dystrophy (DMD). DTIL has reported promising This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of DTIL either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my o
Show less
Read more
Impact Snapshot
Event Time:
DTIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DTIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DTIL alerts
High impacting Precision BioSciences, Inc. news events
Weekly update
A roundup of the hottest topics
DTIL
News
- Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Precision Biosciences: Still Swinging And Finally Drawing Blood [Seeking Alpha]Seeking Alpha
- Precision BioSciences (NASDAQ:DTIL) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025 [Yahoo! Finance]Yahoo! Finance
- Precision BioSciences Announces Presentation of Clinical Data from the ELIMINATE-B Trial at HEP-DART 2025Business Wire
DTIL
Earnings
- 11/3/25 - Miss
DTIL
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- 12/17/25 - Form 4
- DTIL's page on the SEC website